The 2022 World Health Organization (WHO) guidelines classify GH-secreting pituitary adenomas into densely granulated somatotroph tumors (DGSTs) and sparsely granulated somatotroph adenomas (SGSTs) based on GH immunoreactivity and cytokeratin patterns (8). This evidence concerns the gene GH1 and growth hormone-secreting pituitary adenoma.